When Healthcare Policy Incentives Backfire: 340B, Hospital Pricing, MFN, and Drug Affordability with Deborah Williams
Healthcare policies are often evaluated by what they are intended to accomplish. But what happens when the incentives created by those policies produce very different results?
In this episode of RealPharma, Ian Wendt and Dr. Na-Ri Oh speak with longtime health policy expert Deborah Williams about the unintended consequences embedded in the U.S. healthcare system—from hospital reimbursement and industry consolidation to the 340B Drug Pricing Program, biosimilars, most-favored-nation pricing, and pharmaceutical innovation.
Deborah argues that healthcare policy must be judged not by its stated purpose, but by the behaviors, financial incentives, and measurable outcomes it creates. The discussion examines why transparency alone may not lower healthcare costs, how hospital systems use their political and economic influence, and why policies designed to improve affordability can sometimes contribute to higher prices.
The conversation also explores the practical and constitutional uncertainties surrounding most-favored-nation drug pricing, the Trump administration’s GARD, GLOBE, and GENEROUS models, and the potential downstream effects of pricing reform on research, development, manufacturing, and patient access.
Topics Discussed
Why healthcare policy should be evaluated by results rather than intentionsThe history and limitations of diagnosis-related groups, or DRGsWhy MACRA has failed to create an effective physician payment systemWhether healthcare price transparency can meaningfully reduce costsThe effects of hospital consolidation and certificate-of-need lawsWhy hospital systems have become so politically difficult to challengeIndiana’s effort to cap hospital prices relative to Medicare ratesThe widening divide between large health systems and rural hospitalsHow nonprofit hospitals deploy capital and justify tax-exempt statusThe role of hospital employment in local political influenceWhy 340B purchasing incentives can favor higher-priced branded productsHow 340B spreads may undermine biosimilar adoptionWhether 340B savings are reaching vulnerable patientsAlternatives to funding safety-net and uncompensated-care services through drug discountsWhy policymakers may need to separate hospital support from pharmaceutical pricingThe rationale behind most-favored-nation drug pricingWhether European countries are likely to pay more for pharmaceuticalsHow Medicaid best-price rules affect commercial contractingThe relationship between direct-to-consumer pricing and 340B exposureGARD, GLOBE, and GENEROUS drug-pricing modelsThe legal and constitutional questions surrounding mandatory drug rebatesPharmaceutical manufacturing reshoring and national economic policyHow interest rates and global reimbursement policies affect drug developmentThe need to measure the quality—not merely the quantity—of pharmaceutical innovationWhy every healthcare payment system has both intended and unintended consequencesKey Takeaways
Policy intentions do not guarantee beneficial outcomes
Even carefully designed reimbursement systems can produce distortions once stakeholders respond to the incentives. Deborah emphasizes that policymakers must continuously measure what happens after implementation rather than assuming a program is working because its goals are admirable.
Transparency is necessary, but not sufficient
Publishing hospital prices may help patients and purchasers compare costs, but transparency has limited value when every available option is still unaffordable. Meaningful reform may also require addressing hospital concentration, market power, and state certificate-of-need restrictions.
Hospitals possess considerable economic and political power
Large health systems are often among the biggest employers in a congressional district or state. That employment base, combined with campaign contributions and community influence, makes hospital payment reform politically difficult—even when prices and capital spending appear difficult to justify.
The 340B program can create incentives that conflict with affordability
The discussion examines how hospitals may earn substantial spreads between the discounted acquisition cost of a drug and the amount ultimately reimbursed. Those spreads can influence product selection, encourage use of higher-priced brands, and weaken the competitive position of lower-cost biosimilars.
Safety-net funding should be tied to services society wants to support
Rather than indirectly subsidizing hospitals through drug-pricing spreads, Deborah suggests that policymakers consider more direct support for uncompensated care, emergency services, obstetrics, psychiatric care, and other socially valuable services.
Most-favored-nation pricing remains highly uncertain
MFN policies may be politically attractive because Americans pay more for many medicines than patients in other developed countries. However, other countries may be unwilling or unable to increase their spending, leaving manufacturers to absorb much of the financial impact in the United States.
Drug-pricing rules interact in complicated ways
Best-price requirements, 340B discounts, Medicare reimbursement, direct-to-consumer models, and international reference pricing cannot be evaluated in isolation. A change in one area can cascade through the rest of the pharmaceutical pricing system.
Innovation should be measured by scientific and clinical value
Deborah argues that policy analysis should move beyond simply estimating how many drugs might be lost under a pricing reform. The more important question is whether policies reduce the development of first-in-class therapies, novel mechanisms, and clinically meaningful advances.
